Tenormin/myocardial infarction trial
Executive Summary
Treatment with Stuart's Tenormin (atenolol) in the early stages of suspected myocardial infarction reduced mortality by 15% compared to standard therapy, according to a study reported in the July 12 Lancet. The ISIS (International Study on Infarcet Survival) trial, conducted by Peter Sleight of Oxford University, was three and a half years in duration and involved 16,00 patients from 247 centers in 14 countries. Press release on study says "the most beneficial effects on mortality occurred in the first 48 hours" among patients who received I.V. beta blocker.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.